Page 30,
Strengthening and
broadening our
product portfolio
3 Submitted 165 products across all our markets
3 Signed three new in-licence agreements
3 Received approval for first biosimilar product, Remsima,
in-licensed from Celltrion
3 Submitted first product in a pre-filled syringe
to the US FDA
3 Increase investment in internal R&D
3 Re-launch the first Bedford products to the US market
3 Submit additional products in pre-filled syringes
Maintaining high
UNS Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held